Mylan Launches Generic Frova Tablets In U.S. - Quick Facts

(RTTNews) - Pharmaceutical company Mylan N.V. (MYL) said it launched Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova Tablets, in the U.S.

Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA for this product, which is used to treat acute migraine headaches in adults.

According to IMS Health, Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of about $88.3 million for the 12 months ending March 31, 2016.

Currently, Mylan has 260 ANDAs pending FDA approval, representing $109.1 billion in annual brand sales, according to IMS Health. Forty-seven of these pending ANDAs are potential first-to-file opportunities, representing $37.5 billion in annual brand sales, for the 12 months ending December 31, 2015.